Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer
This study consists of a prospective clinical trial which aims to evaluate the impact of stent insertion for palliation of malignant dysphagia. The main goal being to examine the number of days required following stenting in order to have significant improvement in dysphagia and the length of time that this baseline is maintained. Approximately 100 patients will be prospectively enrolled in this study.
Patients with end stage inoperable esophageal cancer deemed candidates for intraluminal esophageal palliative stent insertion will be prospectively enrolled into the study. Patients with esophageal obstruction or stricture due to other benign causes, tumors obstructing the cervical esophagus, as well as patients with airway-esophageal fistulas will be excluded from the study.
The investigators plan to evaluate the efficacy of intra-esophageal stent insertion to improve malignant dysphagia as a main factor affecting the quality of life in these patients.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer (CT0023)|
- improvement of dysphagia post stenting [ Time Frame: 3 months ] [ Designated as safety issue: No ]To assess the effectiveness of esophageal stenting in improving malignant dysphagia and assess the time period relating to this improvement
- Quality of life post stenting [ Time Frame: 3 months ] [ Designated as safety issue: No ]To assess the effectiveness of esophageal stenting in improving quality of life and assess the time period relating to this improvement
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||August 2017|
|Estimated Primary Completion Date:||June 2017 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01471249
|Centre Hospitalier de l'Université de Montréal|
|Montréal, Quebec, Canada, H2L 4M1|
|Principal Investigator:||Moishe Liberman, MD, PhD||CHUM-Centre Universitaire de Montreal|